On the other hand if a Major Pharma were to make a bid for $ACTC would anything less than $1 bil be a fair value. IMO absolutely not. Meanwhile Roche to Buy InterMune for $8.3 Billion InterMune, based in Brisbane, Calif., has one product on the market: a drug called pirfenidone to treat idiopathic pulmonary fibrosis, a fatal scarring of the lungs. InterMune, which is still not profitable, sells pirfenidone under the name Esbriet in Europe and Canada, where it received regulatory approval in 2011 and 2012. The drug could receive approval in the United States by Nov. 23. http://dealbook.nytimes.com/2014/08/24/roche-to-buy-drug-maker-intermune-for-8-3-billion/?_php=true&_type=blogs&_php=true&_type=blogs&_php=true&_type=blogs&_r=2